Sentences with phrase «treatments in human patients»

Not exact matches

No. 2: Alzheimer's disease treatment nets a breakthrough Roughly 99 % of all Alzheimer's drugs to enter human trials have ended up in the trash heap, but trials are under way evaluating drugs that could soon reshape patient treatment.

This is done routinely in experiments with animals and occasionally with human patients undergoing neurological treatment.

A dozen human studies of MDMA, LSD, a powerful African drug called ibogaine and psilocybin, from so - called «magic mushrooms,» are now under way, testing the once - stigmatized drugs as treatments for not only PTSD, but also cluster headaches and addiction, as well as anxiety and depression in cancer patients.

ASMI researchers are involved in different fields such as biomechanics (motion analysis, which includes cadaver research, namely, the use of human limbs to analyze anatomy, motion, and the strength of muscles, tendons, ligaments, and bones) and clinical research (tracking patients to see how successful they are returning to sport after treatment with surgery or physical therapy).

By promoting DNA demethylation, high - dose vitamin C treatment induced stem cells to mature, and also suppressed the growth of leukemia cancer stem cells from human patients implanted in mice.

To that end, in collaboration with the University of Zurich and MD Anderson Cancer Center, the researchers tested melanoma tumor samples from human patients undergoing treatment with the same targeted therapies.

Scientists want to be able to clone early human embryos, using cells from patients with various diseases, so they can study the diseases in the lab and develop new treatments for them.

Mathias Uhlen, director of the Human Protein Atlas project and co-author of the paper, says: «I am extremely pleased that the resource created through the Human Protein Atlas effort has been used in the analysis of clinical data obtained from liver disease patients and that this analysis has led to the identification of liver - specific drug targets that can be used for treatment of this clinically important patient group.»

The antibiotic minocycline seemed to be a promising treatment for ALS in mice, so why was it so hard to recruit ALS patients for a human trial?

Additional experiments using a combination of maraviroc and a drug that blocks the VEGF protein suggest that the treatment duo could be an effective way to prevent metastatic disease in human breast cancer patients, according to the researchers.

The use of bone marrow - derived stem cells is well established in the treatment of human cancer patients, and veterinary applications for bone marrow - and adipose - derived stem cells are being evaluated.

University of Alabama at Birmingham researchers have found that amounts of this microRNA are significantly elevated in the brains of experimental rats with induced depression from corticosterone treatment, in the post-death brains of humans diagnosed with MDD and in peripheral blood serum from living patients with MDD, according to a study by led by Yogesh Dwivedi, Ph.D., the Elesabeth Ridgely Shook Endowed Professor and director of Translational Research, UAB Mood Disorders Program, Department of Psychiatry.

However the fact that Ciclopirox is already approved for treatment of patients by the FDA and by its European counterpart, the EMA, and therefore considered safe for human use, may eliminate much of the time and expense ordinarily involved in the drug development process.

In order to formally introduce this treatment to modern dentistry, however, the researchers will need to perform clinical trials with human patients.

But to try the treatment in patients, they will have to identify the mouse proteins» human equivalents first.

Buoyed by these results, Dana - Farber researchers are working to create a derivative of dBET1 that can be used as a drug in human patients — and to extend the conjugate strategy for the treatment of other cancers and other genetically - caused diseases.

An antibody engineered to prevent excessive bleeding in patients with severe hemophilia A may be safe and effective, and require fewer injections than existing options, according to a first - in - human study of the treatment published online today in Blood, the Journal of the American Society of Hematology (ASH).

After confirming in mouse models that cells from HER2 - positive breast cancers became resistant to anti-HER2 treatment when implanted into the brain but not into other tissues, the investigators found that HER3 is overexpressed in brain metastases of HER2 - positive breast cancers from both mice and human patients.

«But a great deal of work lies ahead to see if this compound has the potential to serve as a less toxic treatment for fungal infections in human patients.

«If dexamethasone works well in humans, we could potentially use it to prevent fearful memories in soldiers on the battlefield, patients in emergency rooms, or anywhere else where healthcare providers provide treatment within hours of traumatic events.»

«Based on this research, we are now conducting a first - in - human study combining the PARP inhibitor with radiation and chemotherapy in patients with locally advanced pancreatic cancer, with an ultimate goal of improving survival rates and treatment outcomes,» said Tuli.

«If we could find human rheumatoid arthritis patients carrying a defect in degrading DNA in macrophages, a new treatment would be developed,» says Nagata.

Guselkumab, a fully human monoclonal antibody targeting IL - 23, in this Phase 2 study for the treatment of PsA, was well tolerated with no unexpected safety findings in this patient population.2 Guselkumab is now being pursued in a Phase 3 development programme for psoriatic arthritis.

Our finding of similarity in clinical progression between human patients and Huntington's disease monkeys suggests monkeys could become a preclinical, large animal model for the development of new treatments.»

The pigs showed both movement problems and respiratory difficulties common to human patients, and it is hoped that this model will assist in the creation of new treatments for Huntington's — a genetically inherited and fatal disease which affects tens of thousands of people.

In a 1988 paper summarizing his findings, Fiebig concluded that xenograft mice were wonderful models for broadly testing new drugs against human tumors, but they «can not be used as a clinical routine method» for predicting patient treatment.1 The idea of using xenograft mice as personal avatars for cancer patients was discarded.

And there are a lot of treatments, or let's say potential treatments, that are working wonderfully in preclinical models that are ready to make the leap to human testing, and some of these have begun to make that transition to bridge from the laboratory to human - patient testing.

Of special note today: gut microbiota species expressing orthologs of human Ro60 might be involved in triggering and sustaining chronic autoimmunity in lupus; The portal vein blood microbiome in patients with liver cirrhosis; A randomized clinical study suggests dietary promotion of short chain fatty acid producing gut microbes as an effective treatment for type 2 diabetes; and the sexual dimorphism of root, flower and leaf microbiomes in the wild strawberry plant

If it can be repeated in humans it would be a breakthrough in the treatment of patients with heart disease and could save thousands of lives.

The aim of this clinical trial is to replicate in humans the same results observed in mice and, ultimately, lead to an effective, nontoxic treatment for newly diagnosed patients as well as patients who can no longer benefit from conventional treatments.

Today a professor of Pediatrics, Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine, and an investigator at the Howard Hughes Medical Institute, Dr. Zoghbi says her ultimate professional goal is «to actually make a patient better» through treatments resulting from her discoveries in research.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Successfully carried out in rats, dogs, monkeys and humans, this treatment requires the patient to take immune - suppressants to prevent rejection.

While many of treatments were able to shift biomarkers in human subjects as they did animal models, they did not improve or stabilize the cognitive performance and functional status of the patients.

We can envision that DAXX can serve as a precise prognostic marker in PCa and that tissue - specific shRNA delivery targeted against DAXX can be employed in the treatment of metastatic prostate cancer in patients, in particular if we discover, through additional studies, that DAXX is a marker for lethal PCa in humans.

Dr. Falk is also PI of an NIH, pharma, and philanthropic funded translational research laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic - based respiratory chain dysfunction, and directs multiple clinical treatment trials in mitochondrial disease patients.

And, indeed, small clinical trials in humans have shown patients report less fatigue and fewer gastrointestinal symptoms while fasting during chemotherapy treatments.

These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen receptor (ER)- positive, human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.

The next step in this ongoing research project involved translating the findings from basic research into applied clinical research with experimental treatment of human cancer patients.

Dr. Cornelius Moerman was a country medical doctor in Holland who fine - tuned his diet over many years by treating both pigeons and then human patients who voluntarily went through his treatment plans.

In the meantime, the results of experiments in animals and humans suggest that lipid - lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short - term risk of coronary heart diseasIn the meantime, the results of experiments in animals and humans suggest that lipid - lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short - term risk of coronary heart diseasin animals and humans suggest that lipid - lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short - term risk of coronary heart diseasin patients at high short - term risk of coronary heart disease.

CHAPTER 1 Indications, Screening, and Contraindications Associated with Bariatric Surgeries Obesity Trends and Consequences Criteria for Bariatric Surgery in Adults Contraindications to Bariatric Surgery CHAPTER 2 Types and History of Bariatric Surgery Broad Categories of Bariatric Procedures History and Time - line of Bariatric Surgery Procedures Restrictive - Malabsorptive Surgery: Roux - en Y Gastric Bypass Purely Restrictive Bariatric Procedures Purely Malabsorptive Procedures Experimental or Investigational Procedures CHAPTER 3 Benefits and Risks of Bariatric Surgery Benefits of Bariatric Surgery Complications of Bariatric Surgery Consequences of Surgery Which May Impact Nutritional Status CHAPTER 4 Perioperative Nutrition Recommendations for Bariatric Surgery Patients Multidisciplinary Approach Prior to Surgery Preoperative Nutrition Guidelines Postoperative Nutrition Assessment and Follow - up Diet Progression Recommendations for Adjustable Gastric Band Diet Progression Recommendations for Roux - en Y Gastric Bypass or Sleeve Gastrectomy Diet Progression Recommendations for Biliopancreatic Diversion (BPD) Vitamin and Mineral Supplementation Exercise CHAPTER 5 The Power of Protein: What the Nutrition Professional Should Know Overview Role of Protein in the Body Sources of Protein Digestion and Absorption of Protein Digestion Rate Upper Limits of Protein Digestion Liver Processing and Elimination Protein Requirements in Humans Beneficial Roles of Protein: Muscle Protein Synthesis, Glucose and Lipid Homeostasis, Thermogenesis and Satiety Muscle Protein Synthesis and Maintenance of Lean Body Mass Glucose and Lipid Homeostasis Thermogenesis and Satiety Protein Malnutrition Preoperative Risk of Protein Malnutrition Postoperative Risk of Protein Malnutrition Protein Prescription for the Bariatric Patient Treatment for Protein Malnutrition in the Bariatric Patient The «30 gram» Protein Myth Liquid or Powder Protein Supplements The Patient's Role Conclusions CHAPTER 6 Micronutrient Deficiencies Associated with Bariatric Surgery Overview Water Soluble Vitamins Thiamin: Overview, Food Sources, Digestion and Metabolism Thiamin Deficiency: Signs and Symptoms Thiamin: Assessment and Treatment of Deficiency Vitamin B12: Overview, Food Sources, Digestion and Metabolism Vitamin B12 Deficiency: Signs and Symptoms Vitamin B12: Assessment and Treatment of Deficiency Folate (folic acid): Overview, Food Sources, Digestion and Metabolism Folate Deficiency: Signs and Symptoms Folate: Assessment and Treatment of Deficiency Fat Soluble Vitamins Vitamin A: Overview, Food Sources, Digestion and Metabolism Vitamin A Deficiency: Signs and Symptoms Vitamin A: Assessment and Treatment of Deficiency Vitamin D and Calcium: Overview, Food Sources, Digestion and Metabolism Vitamin D and Calcium Deficiency: Signs and Symptoms Vitamin D and Calcium: Assessment and Treatment of Deficiency Minerals Iron: Overview, Food Sources, Digestion and Metabolism Iron Deficiency: Signs and Symptoms Iron: Assessment and Treatment of Deficiency Zinc: Overview, Food Sources, Digestion and Metabolism Zinc Deficiency: Signs and Symptoms Zinc: Assessment and Treatment of Deficiency Copper: Overview, Food Sources, Digestion and Metabolism Copper Deficiency: Signs and Symptoms Copper: Assessment and Treatment of Deficiency Selenium: Overview, Food Sources, Digestion and Metabolism Selenium Deficiency: Signs and Symptoms Selenium: Assessment and Treatment of Deficiency Conclusions References Abbreviations and Acronyms Glossary Self Assessment Questions Answer Key to Self Assessment Questions Explanations to Self - Assessment Questions About The Author About Wolf Rinke Associates, Inc..

Unfortunately, there are no guarantees in human or veterinary medicine with any medical or surgical treatment because the ultimate outcome of any medical or surgical therapy depends on the response of the patient receiving treatment.

While there have been some published reports of effective treatment of the virus with human anti-retroviral drugs (eg AZT) used in the treatment of HIV and AIDS, any antiviral benefit is outweighed by negative effects on the patient such as anemia.

Owners are welcome to accompany their pets during the treatment session, but all humans in the room, and the patient wear special protective eye glasses as the laser can damage eye tissue.

With its internationally renowned school of veterinary medicine and its NCI - designated human cancer center, UC Davis is uniquely positioned to evaluate novel treatments for companion dogs with spontaneous tumors that may ultimately be effective in human patients with cancer.

These advancements in the treatment of glaucoma will not only help veterinary patients, but also will translate to improve medical and surgical therapy for humans with glaucoma.

Veterinary medicine has advanced rapidly, paralleling the methods of medical and surgical treatment in human medicine The cost of treating pets has risen due to the added expense of providing more sophisticated treatment in the preventative and life sustaining medical care of our patients.

Researchers in the Modiano Lab, as part of the Animal Cancer Care and Research Program, are working to understand what causes cancer and what drives its behaviors — translating that knowledge into better treatments and, ultimately, fewer cases of cancer in animals and in human patients.

«Unlike humans, our animal patients require anesthesia for their treatments to ensure we are able to get them in the precise position,» explains Dr. Selting.